Hemab Doses First Patient in HMB-003 Phase 1 Trial

Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) reported third quarter 2026 financial results on November 10, 2026, disclosing a net loss of $27.3 million, or $0.58 per share, and cash, cash equivalents and marketable securities of $430.2 million as of September 30, 2026. The clinical-stage biotech also said it dosed the first participant in a Phase 1 trial of HMB-003 for heavy menstrual bleeding and initiated SOLARA, a pivotal Phase 3 study of once-weekly subcutaneous sutacimig in Glanzmann thrombasthenia. Management said the cash balance funds operations into 2029.

Context — why Hemab's Q3 2026 update matters now

The quarter marks Hemab's first full reporting period as a Nasdaq-listed company. The company said its initial public offering closed in May 2026 and that preferred stock converted into common stock at that time. That conversion is why net loss per share fell to $0.58 from $18.04 a year earlier even as the absolute net loss widened, because the weighted-average share count expanded.

Against the prior-year quarter, the cost base moved sharply. Research and development expenses rose to $24.6 million from $14.6 million, and general and administrative expenses rose to $5.1 million from $2.5 million. Hemab attributed the R&D increase to advancing clinical programs, personnel and equity-based compensation, plus discovery and consulting fees tied to company growth.

The catalyst chain is portfolio breadth. Hemab now runs programs from Phase 1 through Phase 3, spanning Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease and heavy menstrual bleeding. Each indication sits in a market the company describes as underserved, and each carries a distinct regulatory pathway.

Macro conditions are not the driver here. Hemab's story rests on clinical readouts and cash runway rather than rate sensitivity, since the company carries no disclosed debt and funds itself from the balance sheet.

Data — what the numbers show

The cash line fell to $430.2 million at September 30, 2026 from $457.5 million at June 30, 2026, a decline of $27.3 million that tracks almost exactly to the quarterly net loss and reflects cash used in operating activities.

Metric	Q3 2026	Q3 2025
Research and development	$24.6M	$14.6M
General and administrative	$5.1M	$2.5M
Net loss	$27.3M	$17.1M
Net loss per share	$0.58	$18.04

On the clinical side, Hemab reported that two participants with severe congenital Factor VII deficiency received a single subcutaneous dose of sutacimig in the Phase 2b single ascending dose cohort. Baseline prothrombin time of at least 180 seconds shortened by more than 50% in both participants, and the participant with pharmacokinetic data showed roughly 5x accumulation of endogenous total FVII(a) with exposure maintained through Day 22.

In the VELORA Pioneer Phase 1/2 trial of HMB-002 in Von Willebrand Disease, Hemab said 8 of 9 evaluable patients across single ascending dose cohorts had zero treated bleeds in the 28 days after dosing, with a mean annualized treated bleed rate of 1.6 versus a baseline mean of 20.1. The company noted the single ascending dose portion was not designed to measure efficacy and called the observations descriptive.

Analysis — what it means for markets and sectors

Hemab sits in the rare-disease and hematology segment of biotechnology, where valuation turns on de-risking events rather than near-term revenue. The SOLARA initiation is the largest such event in the quarter, because it is the first pivotal trial of a subcutaneous prophylactic treatment in Glanzmann thrombasthenia, per the company.

The regulatory detail matters for how investors should read the design. Hemab said the FDA recommended a randomized controlled design, and that it acknowledged the company's feasibility concerns for randomization in GT. Hemab chose a single-arm trial with intra-participant comparison instead. That structure lowers enrollment friction in a rare disease but leaves the primary endpoint exposed to whether the 24-week run-in period captures a stable baseline.

The limitation is worth stating plainly. A single-arm design cannot separate treatment effect from regression to the mean or from seasonal bleeding variation, and the company disclosed no statistical powering detail for the annualized treated bleed rate comparison. Hemab also did not disclose SOLARA's cost, enrollment timeline beyond the fourth quarter of 2026 run-in start, or the terms of any financing beyond the stated runway.

Positioning reflects that uncertainty. Clinical-stage biotechs with a 2029 runway and no revenue typically attract specialist healthcare funds and generalist biotech baskets, while short interest concentrates around binary readouts. Hemab's next binary points are the ASH presentations in December 2026 and the EAHAD data in February 2027.

Outlook — what to watch next

Hemab gave three dated catalysts. Preclinical HMB-003 data will be presented as a poster at the 68th ASH Annual Meeting and Exposition on December 13, 2026. Updated sutacimig data in Factor VII deficiency for all dosed participants will be presented as a poster at the same meeting on December 14, 2026. Additional VELORA Pioneer data for HMB-002 in Von Willebrand Disease is expected at the 20th EAHAD Congress in February 2027.

The company also said it expects initial clinical data from the ongoing HMB-003 Phase 1 trial in mid-2027, and that the first SOLARA participants are scheduled to enter the run-in period in the fourth quarter of 2026. The trial targets roughly 75 participants aged 12 to 70 with at least four treated bleeding events in the prior 12 months, with adolescent enrollment gated by a data safety monitoring committee.

Cash is the constraint to track. Hemab said the $430.2 million funds operations and capital expenditure into 2029, which spans the SOLARA readout window. Any acceleration in R&D spend above the $24.6 million quarterly run rate shortens that runway, and the company disclosed no revenue line to offset it.

Frequently Asked Questions

What does the SOLARA trial mean for Hemab investors?

SOLARA is the first pivotal trial of a subcutaneous prophylactic treatment in Glanzmann thrombasthenia, according to Hemab. It enrolls about 75 participants across a 24-week run-in on standard of care followed by 48 weeks of sutacimig at 0.2 mg/kg weekly. The primary endpoint compares annualized treated bleed rate during prophylaxis against the run-in period, with each participant serving as their own control.

Why did Hemab's net loss per share drop so sharply?

Hemab reported a net loss of $0.58 per share for Q3 2026 versus $18.04 a year earlier, even though the absolute net loss grew to $27.3 million from $17.1 million. The company attributed the per-share decline to a higher weighted-average share count following its May 2026 initial public offering and the conversion of preferred stock into common stock.

What regulatory designations does sutacimig hold?

Hemab said the FDA granted sutacimig Fast Track, Orphan Drug and Breakthrough Therapy designations for Glanzmann thrombasthenia. In Europe, the EMA granted orphan medicinal product status and access to the PRIME scheme, and the UK MHRA awarded an Innovative Licensing and Access Pathway designation. The company has not disclosed whether these designations apply to the Factor VII deficiency program.

Bottom Line

Hemab's cash covers four years of spending, but SOLARA's single-arm design leaves its pivotal Glanzmann thrombasthenia readout carrying the entire clinical narrative.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.